Clinical Outcomes of Oral Zinc Therapy in Hepatic Encephalopathy Treatment.

Megan Kunka Fritz Anthony A ManginoTaylor V HuntC Tyler PitcockAdam J DuganKishore KarriPradeep Yarra

Published in: The Annals of pharmacotherapy (2022)

This is the first study conducted in the United States evaluating zinc for HE treatment. Zinc did not impact 30-day or 1-year all-cause readmission rates. Further studies are warranted to evaluate the potential benefit of zinc for HE, possibly in correlation with Model for End-stage Liver Disease-Sodium (MELD-Na) scores.

Keyphrases

oxide nanoparticles
stem cells
early onset
combination therapy
risk assessment
human health